News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Eleven Biotherapeutics to Present Data on Lead Drug Candidate, EBI-005, at the ARVO 2013 Annual Meeting



4/24/2013 11:42:34 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Eleven Biotherapeutics, a biopharmaceutical company creating novel and differentiated protein-based biotherapeutics for the treatment of ocular diseases, announced today that three poster presentations on its lead drug candidate EBI-005 have been selected for presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2013 Annual Meeting taking place May 5-9, 2013, in Seattle, WA. The presentations will highlight EBI-005 as a new approach to optimize topically applied proteins on the surface of the eye and as the first rationally-designed topically administered IL-1 protein for the treatment of ocular diseases, including dry eye disease. Patient enrollment and dosing has been completed in a Phase 1b clinical study of EBI-005 treating patients with dry eye disease; top-line data is expected in the second half of 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES